Baird analyst Ben Kallo maintains Tesla (NASDAQ:TSLA) with a Outperform and lowers the price target from $316 to $252.
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Adjusts PT To $22 (1:14 Reverse Stock Split)
Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy, adjusts PT to $22 (1:14 reverse stock split).